COMMUNIQUÉS West-GlobeNewswire

CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
15/07/2026
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity Lehi, Utah, July 14, 2026 (GLOBE [...]
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
15/07/2026
WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Spire Healthcare announced as exclusive Team GB Official Healthcare Services Partner
15/07/2026
Organisations join forces for “a healthier, more productive nation” Agreement with Team GB covers the Los Angeles 2028 Olympic Games LONDON, July 15, 2026 (GLOBE NEWSWIRE) -- Spire Healthcare today announces a new [...]
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
15/07/2026
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
14/07/2026
Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV [...]
Spur Therapeutics Announces Executive Transitions
14/07/2026
CEO Michael Parini to Transition to Chair of the Board of Directors, effective July 31, 2026 Samantha Roberts, MD, PhD, Executive Partner at Syncona, to Join as Board Director Henning Stennicke, PhD, CSO, Appointed [...]
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
14/07/2026
Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years AUSTIN, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
14/07/2026
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report [...]
La Plata County continues to improve code revisions
14/07/2026
Commissioners adopted five Land Use Code amendments that shave weeks off permitting timelines and launched a Proposition 123 “fast-track” for affordable housing — the latest steps in a code-reform effort the county [...]
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
14/07/2026
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform [...]
Acquisition of Own Shares
14/07/2026
Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
DBV Technologies présente ses résultats financiers du premier semestre 2026 et fait le point sur ses activités le 16 julliet 2026
14/07/2026
Châtillon, France, le 14 juillet (22:30 CEST) 2026 DBV Technologies présente ses résultats financiers du premier semestre 2026 et fait le point sur ses activités le 16 julliet 2026 DBV La Société organise une conférence [...]
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
14/07/2026
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or [...]
AVITA Medical to Announce Second Quarter 2026 Financial Results
14/07/2026
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, [...]
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
14/07/2026
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it has entered into a five-year [...]
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
14/07/2026
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 [...]
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026
14/07/2026
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market [...]
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
14/07/2026
REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with palbociclib and [...]
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
14/07/2026
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]

Pages